Participant flow12

How many started, completed or left each group, period by period.

1 to 12 of 12

Period	Milestone	Group	Participants
Overall Study	STARTED	Placebo + Chemotherapy	298
Overall Study	STARTED	Atezolizumab + Chemotherapy	297
Overall Study	Safety-evaluable Population	Placebo + Chemotherapy	294
Overall Study	Safety-evaluable Population	Atezolizumab + Chemotherapy	293
Overall Study	Programmed Death-ligand 1 (PD-L1)-Positive Population	Placebo + Chemotherapy	177
Overall Study	Programmed Death-ligand 1 (PD-L1)-Positive Population	Atezolizumab + Chemotherapy	177
Overall Study	Modified Intent-to-Treat (mITT) Population	Placebo + Chemotherapy	192
Overall Study	Modified Intent-to-Treat (mITT) Population	Atezolizumab + Chemotherapy	188
Overall Study	COMPLETED	Placebo + Chemotherapy	0
Overall Study	COMPLETED	Atezolizumab + Chemotherapy	0
Overall Study	NOT COMPLETED	Placebo + Chemotherapy	298
Overall Study	NOT COMPLETED	Atezolizumab + Chemotherapy	297

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT03371017/flow